Form 4: Kathleen Laporte Reports Stock Option Grant in Cero Therapeutics Holdings, Inc.

Kathleen Laporte, a director at Cero Therapeutics Holdings, Inc., reported the acquisition of stock options to purchase 17,923 shares of common stock.

Summary

• Kathleen Laporte, a director of Cero Therapeutics Holdings, Inc., filed a Form 4 on March 6, 2025.
• The report details a transaction on March 4, 2025, where Laporte acquired stock options to purchase 17,923 shares.
• These options have an exercise price of $1.43.
• The options vest over time, with 50% vesting on the twelve-month anniversary of the grant date and the remaining portion subject to performance conditions.
• The reported options expire on March 3, 2035.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC filing related to insider transactions, common for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Key Dates

Keywords

Form 4, Stock Options, Cero Therapeutics Holdings, Inc., Kathleen Laporte, Director, Beneficial Ownership